Lance A. Smith

Adenosine A_2A Antagonist: A novel antiparkinsonian agent that does not provoke dyskinesia in Parkinsonian monkeys

Tomoyuki Kanda, Michael Jackson, Lance A. Smith et al. · Annals of Neurology · 1998 · 356 citations

Medicine, Neuroscience, Pharmacology +16

Combined Use of the Adenosine A2A Antagonist KW-6002 with l-DOPA or with Selective D1 or D2 Dopamine Agonists Increases Antiparkinsonian Activity but Not Dyskinesia in MPTP-Treated Monkeys

Tomoyuki Kanda, Lance A. Smith, R. K. B. Pearce et al. · Experimental Neurology · 2000 · 246 citations

Life Sciences, Neuroscience, Pharmacology +15

A-77636: a potent and selective dopamine D1 receptor agonist with antiparkinsonian activity in marmosets

John W. Kebabian, Donald R. Britton, Michael P. DeNinno et al. · European Journal of Pharmacology · 1992 · 156 citations

Life Sciences, Neuroscience, Pharmacology +14

Multiple small doses of levodopa plus entacapone produce continuous dopaminergic stimulation and reduce dyskinesia induction in MPTP‐treated drug‐naïve primates

Lance A. Smith, Ghassan Al‐Barghouthy, Sarah Rose et al. · Movement Disorders · 2005 · 112 citations · Full text

Medicine, Neuroscience, Pharmacology +14

3,4-Methylenedioxymethamphetamine (Ecstasy) Inhibits Dyskinesia Expression and Normalizes Motor Activity in 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine-Treated Primates

Mahmoud M. Iravani, Mikko Kuoppamäki, Lance A. Smith et al. · Journal of Neuroscience · 2003 · 105 citations · Full text

Medicine, Neuroscience, Pharmacology +15